Rubicon Research, a pharmaceutical company, is conducting its Initial Public Offering (IPO) by offering shares to the public for the first time. The demand for these shares has significantly exceeded the supply, with total demand reaching 22.78 times the available shares. This includes a demand of 20.22 times from retail investors, 9.22 times from institutional investors, and 51.71 times from high-net-worth individuals and companies. The total amount being raised through this IPO is ₹1,377.5 crore, which is allocated as follows: ₹500 crore will be retained by the company, ₹877.5 crore will be distributed to existing investors selling their shares, and ₹310 crore will be used to repay loans, while the remaining funds will support the company’s growth and potential acquisitions.
The price range for each share is set between ₹461 and ₹485, with one lot consisting of 30 shares. Rubicon specializes in developing specialized medicines and invests heavily in research. Key dates to note include the share allotment on October 14 and the commencement of trading on October 16, with listings on both the BSE and NSE. Investors can verify their allotment status through the NSE and BSE websites by entering their PAN and application number or by using the MUFG Intime India platform.
